Golden Gate Bridge, San Francisco, CA

Advisors

Helping Us Succeed

John whisnant

John Whisnant

Dr. Whisnant began part time work in pharmaceutical development after completing his clinical training in pediatrics and a fellowship in immunology at NIH. His experience in drug development has included appointments at the best of Pharma R&D groups, at Wellcome from 1973 to 1987, at DuPont to 1991, and at Fujisawa in 1992. He then had an opportunity to apply medicine and science to business goals including generic drugs at the Ivax Corp from 1992 to 1995. He led North American Clinical Development for Novo Nordisk from 1995 to 2002, which included successful registration of products in diabetes, women’s healthcare and hemophilia.

In the last 10 years, Dr. Whisnant has been consultant on clinical, regulatory and strategic business projects for multiple pharma and biotech companies; he founded Product Development Resources, LLC and has worked with excellent colleagues at Kinexum Services, LLC and Pharmaceutical Advisors, LLC. Consulting assignments have included ad hoc appointments as CMO, VP Development, Medical Monitor, and team leader for drugs and biologics in oncology, diabetes/metabolism, immunology and others.

Dan bradbury

Dan Bradbury

Dan Bradbury is a Life Sciences Executive with over 30 years of experience creating and implementing strategies that transform businesses, bring novel medicines to market and maximize shareholder value. He is the Managing Member of BioBrit, LLC, a Life Sciences Consulting and Investment Firm.

Dan is the former President, Chief Executive Officer and Director of Amylin Pharmaceuticals, a biopharmaceutical company based in San Diego, CA, focused on metabolic diseases. During his 18-year tenure at Amylin, the company launched three firstin-class medicines, including the first once-a-week therapy to treat diabetes and was listed on the Nasdaq 100. He served as Amylin’s Chief Executive Officer from March 2007 until its acquisition by Bristol-Myers Squibb Company for $7 billion in August 2012. Before joining Amylin, Dan worked in marketing and sales roles for ten years at SmithKline Beecham Pharmaceuticals. He serves on the board of directors of Biocon Limited (NSE: BIOCON), Corcept Therapeutics (NASDAQ: CORT), Geron Corporation (NASDAQ: GERN), Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), Castle Biosciences, Inc. (Private), DiaVacs, Inc. (Private), Liquid Grids, Inc. (Private), Microdermis, Inc. (Private), ProSciento, Inc., formerly known as Profil Institute of Clinical Research, Inc. (Private), Renova Therapeutics (Private), Sensulin, Inc. (Private) and Thesan Pharmaceuticals, Inc. (Private). He also serves on the board of the Riecken Community Libraries, the board of trustees of the Keck Graduate Institute, the BioMed Ventures Advisory Committee, the University of California San Diego’s Rady School of Management's Advisory Council, the board of ADCY5.org, the Pharming Group N.V. Commercial Advisory Board, the ProLynx, LLC Advisory Board, the Arctic Aurora Life Science Advisory Board and is an advisor to Patricia Industries (a part of Investor AB).

Dan received a Bachelor of Pharmacy from Nottingham University and a Diploma in Management Studies from Harrow and Ealing Colleges of Higher Education in the United Kingdom.

Gary elliott

Gary Elliott

Gary T. Elliott, R.Ph., Pharm.D., Ph.D. brings more than 25 years in the industry including Vice President Product Development and Technical Operations with Salmedix, Adventrx, HuyaBioscience, Corixa, Ribi Immunochem. His experience has been built upon a formal didactive background of Pharmacy, Clinical Pharmacology and Medicinal Chemistry. Dr Elliott has had considerable interaction over the years with US, Canadian and European drug and biologics regulatory authorities, authoring and supervising compilation of many regulatory filings (e.g. INDs, NDAs, annual reports, end of Phase 2, Phase 3 and NDA CMC and clinical technical documents) and experience organizing participating and leading associated face to face and telephonic meetings with regulatory authorities. Primary author of numerous FDA CMC documents, INDs, end of Phase 2 pre-NDA and NDAs, extensive face to face and telephonic interaction with US FDA re clinical preclinical, toxicology and CMC submissions.

Gary brings integrated technical expertise in formulation, analytical, medicinal chemistry and experience and expertise in Natural Products/plant-derived Drug Substance and Drug Product Development including extensive experience in various extraction technologies, structural determination, bioanalytical method development and in vitro and in vivo biological testing. Gary has additionally run pharmacology, toxicology and clinical programs in multiple therapeutic areas including but not limited to infectious disease, immunology, oncology and cardiology. Since the successful sale of Salmedix, Gary has served as a consultant to the industry and is currently a Lead consultant and Partner with Pharmaceutical Advisors LLC.

Werner hafelfinger

Werner Hafelfinger

Mr. Hafelfinger has considerable experience working with medical device companies of various sizes and at various stages of development. From 1984-1999, Mr. Hafelfinger served as the Vice President of Operations and the Vice President of Research and Development for St. Jude Medical. At St. Jude, Mr. Hafelfinger setup including semiconductor operations for the design and manufacturing of medical products. In that position he held worldwide responsibility across multiple operations, including the setup of clinical trials associated with both the FDA and European regulatory agencies. From 1999-2002 Mr. Hafelfinger was the Chief Operating Officer of Pacific Aerospace Electronics, a medical product component manufacturer. From 2002 Mr. Hafelfinger served as Vice President of Operations for Savacor from when it was an early-stage startup developing an implantable left atrial pressure sensor from 2002-2005. Savacor was acquired by St. Jude Medical in 2005, and Mr. Hafelfinger serves again as Vice President of Operations for St. Jude Medical in that acquisition. He is currently responsible for all aspects regarding clinical trials support for the implantable left atrial pressure sensor including engineering, manufacturing and processes.

Mr. Hafelfinger has been involved in establishing processes and compliance for products within startups, documentation, product controls related to shipment and regulatory verifications, and regulatory submission processes for both the U.S. and the European Union.

Francis szoka

Francis Szoka

Dr. Szoka is a professor in the Bioengineering Department in the UCSF School of Pharmacy. The Szoka group applies chemical, biophysical and molecular biology approaches to devise vaccine, drug and nucleic acid delivery systems to treat cancer or infectious diseases. These systems utilize lipids, peptides, polymers and proteins. The current focus in his group is on cell-based therapies using macrophages. The group has extensively investigated the role of lipids in membrane fusion and has designed, synthesized, and studied the mechanism of fusogenic peptides. With group members, Dr. Szoka has published over 210 manuscripts and has received 29 U.S. patents. One FDA approved drug product, Amphotec™, and one biotechnology product, Superfect™, have been commercialized from the patents.

In addition to his university commitments, Dr. Szoka is a founder of Sequus Pharmaceuticals, Inc. which introduced Doxil©, GeneMedicine, Inc., and ZoneOne Pharma, Inc., a company that is devising chelation treatments for thalassemia.